Abstract
CD38 is regarded as a potential target. Inhibitors against CD38 can regulate calcium metabolism in human body to impede the occurrence of disease, including diabetes and myeloma. In this work, 47 thiazoloquin(az)olin(on)es analogues with high pIC50 values in the micromolar ranges are studied by three-dimensional quantitative structure-activity relationship (3D-QSAR) and molecular docking. The comparative molecule field analysis (i.e., CoMFA q2 = 0.790; r2 = 0.967; rpred 2 = 0.872) and comparative molecular similarity indices analysis (i.e., CoMSIA q2 = 0.723; r2 = 0.969; rpred 2 = 0.815) are applied. Then, the Topomer CoMFA method is performed to validate these models, and the results show that this model has q2 = 0.662, r2 = 0.915 and rpred 2 = 0.704. These results indicate that the three models have good predictive abilities. Subsequently, molecular docking highlights the important interactions between the ligand and the CD38 receptor protein.
Keywords: 3D-QDAR, docking, CD38 inhibitor, Topomer CoMFA, CoMFA, CoMSIA
Letters in Drug Design & Discovery
Title:Identification of Thiazoloquin(az)olin(on)es Derivatives as CD38 Inhibitors Through 3D-QSAR and Molecular Docking Simulations
Volume: 14 Issue: 2
Author(s): Xiaodong Gao and Yujie Ren
Affiliation:
Keywords: 3D-QDAR, docking, CD38 inhibitor, Topomer CoMFA, CoMFA, CoMSIA
Abstract: CD38 is regarded as a potential target. Inhibitors against CD38 can regulate calcium metabolism in human body to impede the occurrence of disease, including diabetes and myeloma. In this work, 47 thiazoloquin(az)olin(on)es analogues with high pIC50 values in the micromolar ranges are studied by three-dimensional quantitative structure-activity relationship (3D-QSAR) and molecular docking. The comparative molecule field analysis (i.e., CoMFA q2 = 0.790; r2 = 0.967; rpred 2 = 0.872) and comparative molecular similarity indices analysis (i.e., CoMSIA q2 = 0.723; r2 = 0.969; rpred 2 = 0.815) are applied. Then, the Topomer CoMFA method is performed to validate these models, and the results show that this model has q2 = 0.662, r2 = 0.915 and rpred 2 = 0.704. These results indicate that the three models have good predictive abilities. Subsequently, molecular docking highlights the important interactions between the ligand and the CD38 receptor protein.
Export Options
About this article
Cite this article as:
Gao Xiaodong and Ren Yujie, Identification of Thiazoloquin(az)olin(on)es Derivatives as CD38 Inhibitors Through 3D-QSAR and Molecular Docking Simulations, Letters in Drug Design & Discovery 2017; 14 (2) . https://dx.doi.org/10.2174/1570180813666160919121104
DOI https://dx.doi.org/10.2174/1570180813666160919121104 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Bacterial Protein Interaction Networks: Connectivity is Ruled by Gene Conservation, Essentiality and Function
Current Genomics Scanning the Genome of Mycobacterium tuberculosis to Identify Potential Lectins
Protein & Peptide Letters TB Diagnostics – Old and New
Current Respiratory Medicine Reviews Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals Antimycobacterial Activities of Oxazolidinones: A Review
Infectious Disorders - Drug Targets Synthesis and Antitubercular Evaluation on Novel 1-Ethyl-5-(hetero)aryl- 1,6-dihydropyrazine-2,3-dicarbonitriles and 3-Cyano-1-ethyl-5-(hetero) aryl-2(1H)-pyrazinones
Anti-Infective Agents Design, Synthesis and In Vitro Biological Evaluation of Pyridine, Thiadazole, Benzimidazole and Acetyl Thiophene Analogues as Anti Tubercular Agents Targeting Enzyme Inh A
Current Computer-Aided Drug Design Towards a Stratified Targeted Approach with Biologic Treatments in Rheumatoid Arthritis: Role of Synovial Pathobiology
Current Pharmaceutical Design Autoantibodies and Sjogren’s Syndrome: A Physiologist’s Perspective
Current Pharmaceutical Biotechnology Recent Advancements in Antimycobacterial and Antifungal Drugs: A Patent Perspective
Recent Patents on Biotechnology NMN/NaMN Adenylyltransferase (NMNAT) and NAD Kinase (NADK) Inhibitors: Chemistry and Potential Therapeutic Applications
Current Medicinal Chemistry Metals and Metal Derivatives in Medicine
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Current Developments in the Synthesis and Biological Activity of Aza-C-Nucleosides:Immucillins and Related Compounds
Current Medicinal Chemistry Chorismate Synthase: An Attractive Target For Drug Development Against Orphan Diseases
Current Drug Targets Structural Proteomics: Inferring Function from Protein Structure
Current Proteomics Drug Delivery to Captive Asian Elephants - Treating Goliath
Current Drug Delivery Anti-Infective Peptides to Enhance the Host Innate Response: Design, Development and Delivery
Protein & Peptide Letters subject Index To Volume 2
Current Pharmaceutical Biotechnology